Wanbangde Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Wanbangde Pharmaceutical Group Co., Ltd., explained in plain language.
A Chinese pharmaceutical company involved in drug development and manufacturing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a Three-Pronged therapy reboot the brain after injury? Results expected Dec 2026 (estimated)
- Can a natural compound from moss help the brain? a new trial investigates Results expected Dec 2026 (estimated)
-
Can a Brain-Bleed drug protect memory after surgery?
Disease control Not yet recruitingThis study tests whether huperzine A, an injected drug, can help prevent or reduce memory and thinking problems that often follow surgery for a bleeding brain aneurysm. Adults aged 18-70 who had an aneurysm bleed and underwent endovascular or surgical treatment will receive eithe…
Phase 4 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a natural compound from moss help the brain? a new trial investigates
Knowledge-focused Not yet recruitingThis early-stage trial is testing an oral solution of huperzine A, a compound derived from a type of moss, in healthy adults. The study aims to see how the body absorbs and processes the drug at different doses and to check its safety and tolerability. Participants will be random…
Phase 1 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC